AbbVie is acquiring Amgen-backed DJS Antibodies for $255m while Legend Holdings took part in a $56.6m series C round for VectorBuilder.

M&A DJS Antibodies, the UK-based inflammatory disease-focused antibody therapy developer backed by Amgen, has been acquired by another pharmaceutical firm, AbbVie, for $255m. Amgen unit Amgen Ventures contributed to an $8.4m round for the company in late 2020. Metaverse developer Translucia has purchased Infofed, the Thailand-based esports software platform that counts video game media group…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.